There’s a running joke in RNA therapeutics: you can silence pretty much any gene you want, as long as the problem is in the liver.

It’s been a tough nut to crack for siRNA and ASO drugs since Alnylam cracked the GalNAc code a decade ago. Liver targets? Solved. Everything else? Good luck.

Vivatides Therapeutics just raised $54 million in an oversubscribed Series A to try and change that.

The team over there is building an extrahepatic RNA delivery platform, with the sole intention of getting siRNA and ASO payloads into tissues the liver-focused players can’t reach: heart, muscle, tumors, kidneys.

The round was co-led by Qiming Venture Partners and an unnamed industry fund, with Highlight Capital, TF Capital, and Apricot Capital piling in.

There are plenty of companies chasing this same goal – Dyno comes to mind immediately, along with several others.

Something else caught my eye about this story though.

The company was founded in 2025. They closed a seed round and this Series A within roughly one year.

This doesn’t seem like normal pacing for a preclinical platform play, especially one tackling a delivery problem that’s stumped billion-dollar companies.

The competition in the “get these things out of the liver!” space is real and getting crowded.

Sarepta is using integrin-targeted delivery to get siRNA into muscle for FSHD and myotonic dystrophy, with early Phase 1/2 data showing dose-dependent knockdown.

Aro Biotherapeutics has Phase 1b topline results for a muscle-targeted siRNA in Pompe disease.

Atrium Therapeutics, the company that spun out of Novartis’s Avidity acquisition, launched with $270 million in cash and a cardiac-targeted RNA platform.

Even PeptiDream and Alnylam have been collaborating on peptide-ligand approaches to extrahepatic delivery since 2021.

So what makes Vivatides interesting? In my opinion – it’s the breadth.

Most competitors are going after one tissue: muscle, heart, CNS. Vivatides is positioning as a multi-tissue platform hitting cardiometabolic, hypertension, and oncology targets.

That’s pretty ambitious for a company barely a year old. But the oversubscribed round suggests the delivery data behind closed doors is compelling enough that investors didn’t want to miss it.

The money is going to go toward pushing multiple programs toward IND-enabling studies and building out global R&D infrastructure across their Suzhou and Boston labs.

No specific clinical timelines yet. But at this pace, don’t be surprised if they’re filing an IND before their second birthday.